secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K/A
Filed at:   2026-08-13T20:06:20+00:00
Accession:  0001193125-26-349157
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q2 revenue $909k, up 115% YoY; raises FY26 guidance to $3.75-4.25M
---------------------------------------------------------------------------

- Q2 2026 revenue $909k, up 61% QoQ and 115% YoY; gross margin 84.3%.
- FY2026 revenue guidance raised to $3.75M-$4.25M from prior $3.0M-$4.0M.
- Phase III TIGeR-PaC fully enrolled; completion expected H1 2027, topline H2 2027.
- First commercial RenovoCath use in sarcoma; active cancer centers up to 21 from 16.
- Net loss $2.9M ($0.06/share); cash $9.5M, sufficient into H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000119312526349157/0001193125-26-349157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000119312526349157/rnxt-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer